Literature DB >> 16766771

Ulcerative colitis during CTLA-4Ig therapy in a patient with rheumatoid arthritis.

L M Amezcua-Guerra, B Hernández-Martínez, C Pineda, R Bojalil.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16766771      PMCID： PMC1856333          DOI： 10.1136/gut.2006.095539

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  10 in total

Review 1.  Approaches for identifying and defining environmentally associated rheumatic disorders.

Authors:  F W Miller; E V Hess; D J Clauw; P A Hertzman; T Pincus; R M Silver; M D Mayes; J Varga; T A Medsger; L A Love
Journal:  Arthritis Rheum       Date:  2000-02

2.  Structural analysis of CTLA-4 function in vivo.

Authors:  E L Masteller; E Chuang; A C Mullen; S L Reiner; C B Thompson
Journal:  J Immunol       Date:  2000-05-15       Impact factor: 5.422

3.  Rheumatoid arthritis associated with ulcerative colitis: a case with severe flare of both diseases after delivery.

Authors:  F Boyer; E Fontanges; P Miossec
Journal:  Ann Rheum Dis       Date:  2001-09       Impact factor: 19.103

4.  Liaison between rheumatoid arthritis and ulcerative colitis.

Authors:  Yusuf Aydin; Levent Ozçakar; Mehmet Yildiz; Ayşen Akinci
Journal:  Rheumatol Int       Date:  2002-12-18       Impact factor: 2.631

Review 5.  The B7 family revisited.

Authors:  Rebecca J Greenwald; Gordon J Freeman; Arlene H Sharpe
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

6.  Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution.

Authors:  Frank Heller; Peter Florian; Christian Bojarski; Jan Richter; Melanie Christ; Bernd Hillenbrand; Joachim Mankertz; Alfred H Gitter; Nataly Bürgel; Michael Fromm; Martin Zeitz; Ivan Fuss; Warren Strober; Jörg D Schulzke
Journal:  Gastroenterology       Date:  2005-08       Impact factor: 22.682

Review 7.  The diagnosis of adverse medical events associated with drug treatment.

Authors:  M D Stephens
Journal:  Adverse Drug React Acute Poisoning Rev       Date:  1987

8.  Ulcerative colitis occurring in the course of rheumatoid arthritis: a case successfully treated with mesalamine enema.

Authors:  Kota Sugisaki; Fumiko Honma; Haruyo Iwadate; Kiori Shio; Yasuo Shioya; Etsuko Fukaya; Kaoru Sato; Hiroyuki Saito; Hideharu Sekine; Hiroko Kobayashi; Hiroshi Orikasa; Hiroshi Watanabe; Yukio Sato
Journal:  Intern Med       Date:  2004-11       Impact factor: 1.271

Review 9.  Rheumatoid arthritis associated with ulcerative colitis.

Authors:  Y Adachi; Y Hinoda; H Takahashi; N Nakagawa; H Sakamoto; F Itoh; T Endo; S Suzuki; K Imai
Journal:  J Gastroenterol       Date:  1996-08       Impact factor: 7.527

10.  Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig.

Authors:  Joel M Kremer; Rene Westhovens; Marc Leon; Eduardo Di Giorgio; Rieke Alten; Serge Steinfeld; Anthony Russell; Maxime Dougados; Paul Emery; Isaac F Nuamah; G Rhys Williams; Jean-Claude Becker; David T Hagerty; Larry W Moreland
Journal:  N Engl J Med       Date:  2003-11-13       Impact factor: 91.245
  10 in total
  8 in total

Review 1.  Future therapeutic approaches for inflammatory bowel diseases.

Authors:  Scott E Plevy; Stephan R Targan
Journal:  Gastroenterology       Date:  2011-05       Impact factor: 22.682

Review 2.  Gut inflammation induced by drugs: Can pathology help to differentiate from inflammatory bowel disease?

Authors:  Naoimh Herlihy; Roger Feakins
Journal:  United European Gastroenterol J       Date:  2022-05-28       Impact factor: 6.866

3.  Commensal microbes drive intestinal inflammation by IL-17-producing CD4+ T cells through ICOSL and OX40L costimulation in the absence of B7-1 and B7-2.

Authors:  Lijun Xin; Tony T Jiang; Vandana Chaturvedi; Jeremy M Kinder; James M Ertelt; Jared H Rowe; Kris A Steinbrecher; Sing Sing Way
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-07       Impact factor: 11.205

4.  Candida-elicited murine Th17 cells express high Ctla-4 compared with Th1 cells and are resistant to costimulation blockade.

Authors:  Scott M Krummey; Tamara L Floyd; Danya Liu; Maylene E Wagener; Mingqing Song; Mandy L Ford
Journal:  J Immunol       Date:  2014-02-03       Impact factor: 5.422

5.  Stricturing Crohn's disease-like colitis in a patient treated with belatacept.

Authors:  Anne Bozon; Guillaume Jeantet; Benjamin Rivière; Natalie Funakoshi; Gaspard Dufour; Roman Combes; Jean-Christophe Valats; Sylvie Delmas; Jean Emmanuel Serre; Michael Bismuth; Jeanne Ramos; Moglie Le Quintrec; Pierre Blanc; Guillaume Pineton de Chambrun
Journal:  World J Gastroenterol       Date:  2017-12-28       Impact factor: 5.742

6.  CD28 co-stimulation down regulates Th17 development.

Authors:  Salim Bouguermouh; Geneviève Fortin; Nobuyasu Baba; Manuel Rubio; Marika Sarfati
Journal:  PLoS One       Date:  2009-03-31       Impact factor: 3.240

Review 7.  Co-Stimulatory Blockade of the CD28/CD80-86/CTLA-4 Balance in Transplantation: Impact on Memory T Cells?

Authors:  Simon Ville; Nicolas Poirier; Gilles Blancho; Bernard Vanhove
Journal:  Front Immunol       Date:  2015-08-10       Impact factor: 7.561

8.  Induced Treg Cells Augment the Th17-Mediated Intestinal Inflammatory Response in a CTLA4-Dependent Manner.

Authors:  Nobumasa Watanabe; Osamu Kaminuma; Noriko Kitamura; Takachika Hiroi
Journal:  PLoS One       Date:  2016-03-07       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.